SEARCH

SEARCH BY CITATION

References

  • 1
    Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995;151: 969974.
  • 2
    Bousquet J, Michel FB. Immunotherapy in rhinitis. In: MygingN, PipkornU. editors. Allergic and non-allergic rhinitis: clinical aspects. Copenhagen: Munksgaard, 1992: 136148.
  • 3
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998 ;81: 401405.
  • 4
    Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998;53: 461472.
  • 5
    Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl. 5):S147S334.
  • 6
    Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997;8: 2127.
  • 7
    Guez S, Vatrinet C, Fadel R, Andre C. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000;55: 369375.
  • 8
    Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351: 629632.
  • 9
    Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999;54: 249260.
  • 10
    Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000;55: 842849.
  • 11
    Mungan D, Misirligil Z, Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma – a placebo controlled study. Ann Allergy Asthma Immunol 1999;82: 485490.
  • 12
    Wilson DR, Torres Lima M, Durham SE. Sublingual immunotherapy for allergic rhinitis. The Cochrane Library, 2003, Issue 2, Oxford: Update Software Ltd.
  • 13
    Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med 1990;323: 502507.
  • 14
    Ehnert B, Lau-Schadendorf S, Weber A, Buettner P, Schou C, Wahn U. Reducing domestic exposure to dust mite allergen reduces bronchial hyperreactivity in sensitive children with asthma. J Allergy Clin Immunol 1992;90: 135138.
  • 15
    Weeks J, Oliver J, Birmingham K, Crewes A, Carswell F. A combined approach to reduce mite allergen in the bedroom. Clin Exp Allergy 1995;25: 11791183.
  • 16
    Frederick JM, Warner JO, Jessop WJ, Enander I, Warner JA. Effect of a bed covering system in children with asthma and house dust mite hypersensitivity. Eur Respir J 1997;10: 361366.
  • 17
    Lebel B, Bousquet J, Morel A, Chanal I, Godard P, Michel FB. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass pollen grains. J Allergy Clin Immunol 1998;82: 869877.
  • 18
    Quoix E, Le Mao J, Hoyet C, Pauli G. Prediction of mite allergen levels by guanine measurements in house-dust samples. Allergy 1993;48: 306309.
  • 19
    Kinchi MS, Poulsen LK, Carat F, André C, Malling HJ. Clinical efficacy of sublingual-swallow and subcutaneous immunotherapy in patients with allergic rhinoconjunctivitis due to birch pollen. A double-blind, double-dummy placebo-controlled study. Allergy 2000;63: 24.
  • 20
    Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990;18: 277284.
  • 21
    Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 1999;54: 11101113.
  • 22
    Andre C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000;121: 229234.
  • 23
    Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33: 206210.
  • 24
    Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99: 450453.
  • 25
    Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31: 13921397.